daclizumab

Daclizumab is a humanized monoclonal antibody that binds to CD25, the alpha subunit of the interleukin-2 receptor (IL-2Rα) on T cells. By targeting CD25, daclizumab modulates IL-2-mediated activation of lymphocytes and is presumed to reduce immune activity implicated in autoimmune diseases. It was developed for use as an immunosuppressive agent in organ transplantation (as Zenapax) and later for relapsing forms of multiple sclerosis (as Zinbryta). Daclizumab was approved for MS based on its ability to reduce relapse rates and new lesion formation but was withdrawn from global markets in 2018 due to safety concerns including severe liver injury and autoimmune encephalitis[1][3][5][6].

Brand names

ZinbrytaZenapax

Other names

重组抗CD25人源化单克隆抗体